Clinical trials: Stage II Breast Carcinoma
Breast Cancer, Colorectal Cancer
CI-1040 in Treating Patients With Advanced Breast, Colon, Pancreatic, or Non-Small Cell Lung Cancer
RATIONALE: CI-1040 may stop the growth of tumors by blocking the enzymes necessary for cancer cell growth and by stopping blood flow to the tumor.
- Conditions
- Breast Cancer, Colorectal Cancer, Lung Cancer, Pancreatic Cancer
- Trial name
- NCT00033384
- Testing
- CI-1040
- Where
- United States
- Sponsor
- University of Alabama at Birmingham
Estrogen Receptor-positive Breast Cancer, HER2-negative Breast Cancer
Phase II Study of Everolimus Beyond Progression
This phase II trial studies how well everolimus and hormone therapy work in treating patients with hormone receptor positive breast cancer that has continued to spread (progressed) or returned after a period of improvement…
- Conditions
- Estrogen Receptor-positive Breast Cancer, HER2-negative Breast Cancer, Progesterone Receptor-positive Breast Cancer, Recurrent Breast Cancer
- Trial name
- NCT02269670
- Testing
- everolimus, anastrozole, letrozole
- Where
- 3 sites in United States
- Volunteers
- 3 people
- Sponsor
- Emory University
Breast Cancer
Liposomal Doxorubicin (Lipo-Dox) in Patients With Brain Metastasis From Breast Cancer
Primary objective: To determine the brain response rate of Lipo-Dox in breast cancer patients with brain metastasis Secondary objectives: 1. To determine the overall objective response rate (ORR) 2.
- Trial name
- NCT00465673
- Testing
- Liposomal Doxorubicin
- Where
- Singapore
- Volunteers
- 2 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Chemotherapy-induced Peripheral Neuropathy, Colorectal Cancer Stage II
Effect of Hemp-CBD on Patients With CIPN
The purpose of this study is to assess the effect of a hemp-based cannabidiol (CBD) product, Ananda Hemp Spectrum Gelcaps, on the severity and duration of chemotherapy-induced neuropathy (CIPN) among non-metastatic breast…
- Conditions
- Chemotherapy-induced Peripheral Neuropathy, Colorectal Cancer Stage II, Colorectal Cancer Stage III, Breast Cancer
- Trial name
- Coala-T-CBD (NCT04398446)
- Testing
- Hemp-based CBD
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- Main Line Health
Breast Cancer
Trial of Nivolumab With Chemotherapy as Neoadjuvant Treatment in Inflammatory Breast Cancer (IBC)
Study of efficacy of nivolumab with neoadjuvant chemotherapy in patients with IBC
- Trial name
- NCT03742986
- Testing
- Nivolumab 360mg, Paclitaxel 80mg/m^2, Doxorubicin 60mg/m^2
- Where
- 2 sites in United States
- Volunteers
- 8 people
- Sponsor
- NYU Langone Health
Arthralgia, Breast Cancer
S0927:Omega3-Fatty Acid Supp in Treating Muscle&Bone Pain&Stiffness in Pts W/Stg I,II,III Brst Canc Rec'v Hormone Thpy
RATIONALE: An omega-3 fatty acid-enriched nutritional supplement may help improve muscle and bone pain and stiffness caused by hormone therapy in patients with breast cancer.
- Conditions
- Arthralgia, Breast Cancer, Pain
- Trial name
- NCT01385137
- Testing
- omega-3 fatty acid
- Where
- 292 sites in United States
- Volunteers
- 262 people
- Sponsor
- SWOG Cancer Research Network
Advanced Solid Tumor, Breast Cancer
Combination Therapy of F16IL2 and Doxorubicin in Solid Tumour Patients
This Phase Ib/II study is an openlabel, multicenter study for patients with solid tumors and breast cancer amenable to anthracyclin therapy.
- Trial name
- NCT01131364
- Testing
- F16IL2 in combination with doxorubicin
- Where
- 5 sites in Italy
- Volunteers
- 29 people
- Sponsor
- Philogen S.p.A.
Metastatic Triple Negative Breast Cancer, Metastatic Testicular Cancer
The TASTY-steering Study
This is a multicentre non-blinded randomised intervention trial with a parallel cluster design. The multicentre study will be performed at 12 hospitals in the Netherlands.
- Conditions
- Metastatic Triple Negative Breast Cancer, Metastatic Testicular Cancer, Stage II-IV Diffuse Large B Cell Lymphoma
- Trial name
- TASTY-steering (NCT07258563)
- Testing
- Taste steering
- Where
- 11 sites in Netherlands
- Volunteers
- 201 people
- Sponsor
- University Medical Center Groningen
Metastatic Breast Cancer
A Multicentre Phase I-II Study to Investigate the Combination of Bendamustine With Weekly Paclitaxel as First or Second Line Therapy in Patients With Metastatic Breast Cancer
The aim of the study is to establish a feasible combination of bendamustine and paclitaxel in a weekly schedule. The two agents have different toxicity profiles and are well tolerated when given in a weekly fashion.
- Trial name
- RiTa (NCT00661739)
- Testing
- Bendamustine
- Volunteers
- 38 people
- Sponsor
- GBG Forschungs GmbH
Breast Cancer, HER2-positive Breast Cancer
RC48 for Neoadjuvant Chemotherapy of HER2 Positive Breast Cancer
This is a single-arm exploratory study to explore the effect of RC48 in HER2-positive neoadjuvant therapy and evaluate the non-inferiority of RC48 by comparing the latest reported data of T-DM1 in neoadjuvant therapy.
- Trial name
- NCT05134519
- Testing
- Recombinant humanized anti-HER2 monoclonal antibody-MMAE coupling agent (RC48-ADC)
- Volunteers
- 20 people
- Sponsor
- Xijing Hospital
Advanced Solid Tumors
Evaluating the Safety, Tolerability, and Preliminary Anti-tumor Activity of MB0151 in Adult Subjects With Advanced Solid Tumors Expressing Somatostatin Receptors
This is a multicenter, open-label, single-arm, dose-escalation and dose-expansion Phase I/II study to evaluate the safety, tolerability and preliminary anti-tumor activity of MB0151 in adult subjects (at least 18 years old) with…
- Trial name
- NCT06840821
- Testing
- MB0151 for injection
- Where
- China
- Volunteers
- 156 people
- Sponsor
- Mainline Biosciences (Shanghai) Co., Ltd
Breast Neoplasms, Chemotherapy
Tolerance and Pharmacokinetics With Capecitabine 5 Out of 7 Days Regimen
Standard administration of capecitabine use a 14 days administration. Routine practice in several intitution leads to use a 5 out of 7 days regimen, with less toxicity.
- Trial name
- NCT00324610
- Testing
- capecitabine
- Where
- France
- Volunteers
- 46 people
- Sponsor
- Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie
Breast Cancer, Vaginal Dryness
Pilocarpine in Treating Vaginal Dryness in Patients With Breast Cancer
RATIONALE: Pilocarpine may decrease vaginal dryness and improve quality of life in patients with breast cancer It is not yet known whether pilocarpine is more effective than a placebo in treating vaginal dryness in patients with…
- Trial name
- NCT00343382
- Testing
- pilocarpine hydrochloride
- Where
- 192 sites in United States
- Volunteers
- 201 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Survival
PG2 Breast Cancer Evaluation in Adjuvant Medicine-Survival Study
Astragalus polysaccharides (APS), acting as an immunomodulator, is known to modulate the tumor microenvironment and inhibit tumor growth and progression, thereby suggesting potential as an adjuvant cancer therapy to improve…
- Trial name
- PG2 BEAM-S (NCT07601113)
- Testing
- Astragalus polysaccharides 500 mg
- Where
- 5 sites in Taiwan
- Volunteers
- 66 people
- Sponsor
- Kun-Ming Rau
Breast Cancer
Letrozole in Preventing Cancer in Postmenopausal Women Who Have Received 4-6 Years of Hormone Therapy for Hormone Receptor-Positive, Lymph Node-Positive, Early-Stage Breast Cancer
RATIONALE: Estrogen can cause the growth of breast cancer cells. Letrozole may fight breast cancer by lowering the amount of estrogen the body makes.
- Trial name
- SOLE (NCT00553410)
- Testing
- Letrozole
- Where
- 164 sites in United States, Australia and 18 more
- Volunteers
- 4,884 people
- Sponsor
- ETOP IBCSG Partners Foundation
Breast Cancer Triple Negative, Breast Cancer Stage II
Evaluating and Monitoring Immune and Clinical Responses in Early-Stage Triple Negative Breast Cancer Undergoing Neoadjuvant Chemo-immunotherapy With Pembrolizumab
This research study is a prospective, single arm, pilot study, designed to evaluate the correlation between the immune and clinical responses of subjects with untreated Stage II-III triple negative breast cancer (TNBC) undergoing…
- Conditions
- Breast Cancer Triple Negative, Breast Cancer Stage II, Breast Cancer Stage III, Breast Cancer Invasive
- Trial name
- NCT05877859
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Emory University
Breast Neoplasms
Window of Opportunity Trial of Neoadjuvant Olaparib and Durvalumab for Triple Negative or Low ER+ Breast Cancer
Window of Opportunity Trial of Olaparib and Durvalumab (MEDI4736) before Standard Neoadjuvant Chemotherapy for Stage II/III Triple Negative or Low ER+ Breast Cancer
- Trial name
- NCT03594396
- Testing
- Olaparib, Durvalumab
- Where
- South Korea
- Volunteers
- 54 people
- Sponsor
- Seoul National University Hospital
Metastatic Invasive Breast Cancer, Resistant Breast Cancer
Neu Direction: Testing the Efficacy of Adding HER Inhibition to Standard of Care in Metastatic MLH1-low Endocrine-resistant ER+/HER2- Breast Cancer
The goal of this clinical trial is to learn if neratinib, an FDA-approved oral pan-HER2/3/4 inhibitor, improves disease control for participants with metastatic endocrine-resistant ER+/HER2-negative breast cancer.
- Conditions
- Metastatic Invasive Breast Cancer, Resistant Breast Cancer, ER+, HER2-, Metastatic Breast Cancer
- Trial name
- NCT07729046
- Testing
- Neratinib + endocrine therapy, Endocrine therapy may include one of the following therapies: letrozole, anastrozole, exemestane, tamoxifen or fulvestrant, CDK4/6 + Endocrine therapy
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- University of California, San Diego
Breast Cancer
A Phase II Study of Triple-negative Breast Cancer Brain Metastases.
Study to assess the effectiveness and safety of SHR 1316, bevacizumab combined with cisplatin/carboplatin for treatment of triple-negative breast cancer brain metastases.
- Trial name
- NCT04303988
- Testing
- SHR-1316, Bevacizumab, Cisplatin/Carboplatin
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Fudan University
Cancer
Immunotherapy in Treating Patients Who Are Undergoing Bone Marrow or Peripheral Stem Cell Transplantation
RATIONALE: White blood cells from donors who have been exposed to cytomegalovirus may be able to help prevent this infection from occurring in patients who are undergoing bone marrow or peripheral stem cell transplantation.
- Trial name
- NCT00002673
- Testing
- infection prophylaxis and management
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Fred Hutchinson Cancer Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.